Chasing equitable treatment access for children with TB

Start Sooner. Go Faster.

Children wait years longer than adults for new TB drugs. That delay is preventable. CHEETA is a research consortium accelerating access to new, life-saving tuberculosis treatments for children, cutting a delay that has stretched from 8 to 13 years down toward under two.

The problem

The Science Exists. The System Makes Children Wait.

New TB drugs reach adults years before they reach children. That gap is not a limit of science, it is a limit of how pediatric drug development is organized: trials start too late, run in isolation, and are designed inefficiently.

The result is preventable. Children fall ill and die from a disease we increasingly know how to treat, simply because the treatments arrive too slowly for them.

1.2M

children and young adolescents developed TB in 2024

11%

of new TB infections are in children

16%

of TB deaths are among children

Source: WHO Tuberculosis Report 2025

ADULTSNew TB drug approvedCHILDRENChildren gain access8-13 YEARSTHE GAP CHILDREN WAIT

Our approach

One Coordinated Platform, Built to Move Faster

CHEETA is not a single study or a single drug. It is a shared approach that fixes the sources of delay directly, so many treatments can be evaluated for children more efficiently over time.

Engage developers early

Working with drug developers during their pediatric plans, so trials are designed right from the start and aligned with regulators.

A shared platform trial

One trial infrastructure that can evaluate multiple drugs over time, cutting duplication and speeding evidence.

Trial-ready sites

Coordinated, capable sites in high-burden settings, ready to run pediatric studies well.

Engaging earlier and designing trials more efficiently is what lets CHEETA start sooner and go faster, so children reach new treatments without unnecessary delay.

Explore the platform →

Who it's for

Find Your Way In

Different people come to CHEETA for different reasons. Each of these leads straight to what matters most for that group.

For Funders

The opportunity, the evidence, and the impact of investing in faster access.

Explore →

For TB Drug Developers

How CHEETA de-risks and speeds your pediatric development pathway.

Explore →

For Researchers & Sites

The model, participation criteria, and how to take part in upcoming studies.

Explore →

For Communities & Advocates

What the work means for children, in plain language, and how to stay involved.

Explore →

Progress to date

Already In Motion

CHEETA is a research consortium co-led by Stellenbosch University and the University of Wisconsin-Madison, with the groundwork for trials well underway.

Consortium

Formalized in 2025, co-led by two major universities, evolving from the original task force.

On the world stage

Presented at major scientific meetings, including the Union World Conference on Lung Health.

4 countries

A global site-mapping effort building one of the clearest pictures of pediatric TB trial capacity to date.

Regulators engaged

Active engagement with regulators and the World Health Organization to shape efficient trial pathways.

Under 2 years

The goal: cut the wait for children to access new TB drugs from 8 to 13 years down to under two.

When children reach new treatments years earlier, fewer fall ill and fewer die from a disease we know how to treat. That is the change CHEETA exists to make.

The consortium

A Consortium Built to Deliver

CHEETA brings together scientists, trialists, clinical sites, advocates, regulators, and pharmaceutical partners, the full ecosystem needed to make faster pediatric trials real.

The team carries deep, broad expertise in pediatric TB, clinical trials, pharmacometrics, and global health, a combination that is difficult to replicate.

Meet the people and partners →

Get involved

See Yourself In This Work

Whether you fund, partner, research, or advocate, there is a clear role for you in getting children the treatments they need sooner. Let's start the conversation.

Chasing Expedited and Equitable Treatment Access for Children with TB. A global research consortium accelerating pediatric TB drug development.

Co-led by Stellenbosch University and the University of Wisconsin-Madison

© 2026 CHEETA Consortium